The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

Overview of attention for article published in Frontiers in immunology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 50,895 followers.

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma https://t.co/YmEiIC7o7h https://t.co/DD6xyRU0Pz

07 Feb 2023

Reply Repost Favourite

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma https://t.co/7zKwCMJMId https://t.co/AkL6GKGLOe

20 Jan 2023

Reply Repost Favourite

New Research: The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: Background Neoadjuvant programmed death receptor-1 (PD-1) inhibitor combined with… https://t.co/

20 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.